252 related articles for article (PubMed ID: 32749204)
1. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.
Park HJ; Kim KW; Pyo J; Suh CH; Yoon S; Hatabu H; Nishino M
Radiology; 2020 Oct; 297(1):87-96. PubMed ID: 32749204
[TBL] [Abstract][Full Text] [Related]
2. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
4. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Lee AJ; Kim KW; Cho YC; Ko Y; Sung YS; Shin Y; Lee J; Kim MH
J Clin Med; 2021 May; 10(11):. PubMed ID: 34071024
[TBL] [Abstract][Full Text] [Related]
6. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
8. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Mushti SL; Mulkey F; Tang S; Singh H; Lemery SJ; Goldberg KB; Sridhara R; Keegan P; Kluetz PG; Pazdur R; Theoret MR; Beaver JA
Curr Oncol Rep; 2020 Aug; 22(11):116. PubMed ID: 32851542
[TBL] [Abstract][Full Text] [Related]
9. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.
Urban H; Steidl E; Hattingen E; Filipski K; Meissner M; Sebastian M; Koch A; Strzelczyk A; Forster MT; Baumgarten P; Ronellenfitsch MW; Steinbach JP; Voss M
Front Immunol; 2021; 12():798811. PubMed ID: 35046955
[TBL] [Abstract][Full Text] [Related]
11. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
12. Elevated tumor markers for monitoring tumor response to immunotherapy.
Yang Y; Jiang X; Liu Y; Huang H; Xiong Y; Xiao H; Gong K; Li X; Kuang X; Yang X
EClinicalMedicine; 2022 Apr; 46():101381. PubMed ID: 35434583
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.
Manitz J; D'Angelo SP; Apolo AB; Eggleton SP; Bajars M; Bohnsack O; Gulley JL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228264
[TBL] [Abstract][Full Text] [Related]
14. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
15. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892
[TBL] [Abstract][Full Text] [Related]
16. Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.
Zhou H; Luo Q; Wu W; Li N; Yang C; Zou L
Front Immunol; 2023; 14():1088874. PubMed ID: 36936913
[TBL] [Abstract][Full Text] [Related]
17. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Mönch S; Heimer MM; Winkelmann M; Guertler A; Schlaak M; Tufman A; Ben Khaled N; de Toni E; Westphalen CB; von Bergwelt-Baildon M; Dinkel J; Kazmierczak PM; Ingrisch M; Mansour N; Unterrainer M; Heinzerling L; Ricke J; Kunz WG
Cancer Imaging; 2023 Jun; 23(1):58. PubMed ID: 37291665
[TBL] [Abstract][Full Text] [Related]
18. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
Petrelli F; Ghidini M; Ghidini A; Tomasello G
JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
[TBL] [Abstract][Full Text] [Related]
20. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.
Vrankar M; Unk M
Radiol Oncol; 2018 Oct; 52(4):365-369. PubMed ID: 30367809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
